en · de · es
aod-9604-notes.peptides4962.com › Info › Background And Molecular Identity — 2026 Update

Background And Molecular Identity — 2026 Update

By Editorial Desk · published 2026-03-10 · last reviewed 2026-04-26 · Info

A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-04-26 and is reviewed periodically as new material appears.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Mechanism And Metabolic Effects

Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideBased on the C-terminal region of human growth hormone.
Amino acid length16 residuesOften described as hGH fragment 176-191.
AppearanceLyophilized powderTypically white to off-white; exact appearance depends on grade.
SolubilitySoluble in waterAqueous solubility depends on pH, ionic strength, and preparation.
Typical storage-20 °C or lowerLyophilized peptide is usually kept cold and dry; solutions may require freezing.

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Related pages on this site

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Reference notes

=== Spinal disc disease === Spinal disc disease occurs when the nucleus pulposus, a gel-like material in the inner core of the vertebral disc, ruptures. Rupturing of the nucleus pulposus can lead to compression of nerve roots. Symptoms may be unilateral or bilateral, and correlate to the region of the spine affected. The most common region for spinal disk disease is at L4–L5 or L5–S1. The risk for lumbar disc disease is increased in overweight individuals because of the increased compressive force on the nucleus pulposus, and is twice as likely to occur in men. A 2002 study found that lifestyle factors such as night-shift work and lack of physical activity can also increase the risk of lumbar disc disease. Severe spinal-cord compression is considered a surgical emergency and requires decompression to preserve motor and sensory function. Cauda equina syndrome involves severe compression of the cauda equina and presents initially with pain followed by motor and sensory dysfunction. Bladder incontinence is seen in later stages of cauda equina syndrome.

== A == Abidi alkyne synthesis Acetalisation Acetoacetic ester condensation Achmatowicz reaction Acylation Acyloin condensation Adams' catalyst Adams decarboxylation Adkins catalyst Adkins–Peterson reaction Akabori amino acid reaction Alcohol oxidation Alder ene reaction Alder–Stein rules Aldol addition Aldol condensation Algar–Flynn–Oyamada reaction Alkylimino-de-oxo-bisubstitution Alkyne trimerisation Alkyne zipper reaction Allan–Robinson reaction Allylic rearrangement Amadori rearrangement Amine alkylation Angeli–Rimini reaction Andrussov oxidation Appel reaction Arbuzov reaction, Arbusow reaction Arens–Van Dorp synthesis, Isler modification Aromatic nitration Arndt–Eistert synthesis Aston–Greenburg rearrangement Auwers synthesis Aza-Cope rearrangement Azo coupling

=== Protocol example === A ZooMS protocol (Fig. 1) typically consists of an extraction, denaturation, digestion and filtration step, followed by mass spectrometric analysis. Various destructive and non-destructive extraction protocols have already been discussed in some detail above. The key is to extract the protein preserved in the sample and then bring it into solution, usually an ammonium bicarbonate buffer. Denaturation is done to unfold the proteins and make them more accessible for the enzymatic digestion. It is done by heating the solubilised sample at around 65 °C. Then an enzyme, trypsin, is added to the solution. Trypsin cleaves the protein after every arginine or lysine amino acid in its sequence, resulting in peptide fragments of predictable masses. After digestion the sample is filtered with C18 filters to get rid of non-proteinaceous material and the sample is now ready for mass spectrometric analysis, which for ZooMS generally means MALDI-TOF MS.

Sources: en.wikipedia.org

Reference notes

ColVI plays an important role in cancer by acting as a chemotherapy resistance modulator. ColVI inhibits oxidative damage and apoptosis. ColVI regulates cell differentiation and autophagic machinery. With the assistance of other collagens, proteoglycans, matrilineal, fibronectins, and glycoproteins, ColVI anchors the basement membrane of the skin to the extracellular matrix.

== Bulk properties == Thorium is a moderately soft, paramagnetic, bright silvery radioactive actinide metal that can be bent or shaped. In the periodic table, it lies to the right of actinium, to the left of protactinium, and below cerium. Pure thorium is very ductile and, as normal for metals, can be cold-rolled, swaged, and drawn. At room temperature, thorium metal has a face-centred cubic crystal structure; it has two other forms, one at high temperature (over 1360 °C; body-centred cubic) and one at high pressure (around 100 GPa; body-centred tetragonal). Thorium metal has a bulk modulus (a measure of resistance to compression of a material) of 54 GPa, about the same as tin's (58.2 GPa). Aluminium's is 75.2 GPa; copper's is 137.8 GPa; and mild steel's is 160–169 GPa. Thorium is about as hard as soft steel, so when heated it can be rolled into sheets and pulled into wire. Thorium is nearly half as dense as uranium and plutonium and is harder than both. Thorium has a magnetic susceptibility of 0.412 × 4π × 10−9 m3⋅kg−1 at room temperature. This susceptibility is mostly temperature-independent, however impurities and dopants can affect this value. It becomes superconductive below 1.4 K. Thorium's melting point of 1750 °C is above both those of actinium (1227 °C) and protactinium (1568 °C).

Religious leaders often turned to versions of exorcism to treat mental disorders often utilizing methods that many consider to be cruel or barbaric methods. Trepanning was one of these methods used throughout history. In the 6th century AD, Lin Xie carried out an early psychological experiment, in which he asked people to draw a square with one hand and at the same time draw a circle with the other (ostensibly to test people's vulnerability to distraction). It has been cited that this was an early psychiatric experiment. The Islamic Golden Age fostered early studies in Islamic psychology and psychiatry, with many scholars writing about mental disorders. The Persian physician Muhammad ibn Zakariya al-Razi, also known as "Rhazes", wrote texts about psychiatric conditions in the 9th century. As chief physician of a hospital in Baghdad, he was also the director of one of the first bimaristans in the world. The first bimaristan was founded in Baghdad in the 9th century, and several others of increasing complexity were created throughout the Arab world in the following centuries. Some of the bimaristans contained wards dedicated to the care of mentally ill patients. During the Middle Ages, Psychiatric hospitals and lunatic asylums were built and expanded throughout Europe. Specialist hospitals such as Bethlem Royal Hospital in London were built in medieval Europe from the 13th century to treat mental disorders, but were used only as custodial institutions and did not provide any type of treatment. It is the oldest extant psychiatric hospital in the world.

Sources: en.wikipedia.org

Reference notes

Casein ( KAY-seen; from Latin caseus, 'cheese') is a family of related phosphoproteins (αS1, aS2, β, κ) that are commonly found in mammalian milk, comprising about 80% of the proteins in cow's milk and between 20% and 60% of the proteins in human milk. Sheep and cow milk have a higher casein content than other types of milk with human milk having a particularly low casein content. Casein does not appear to be essential in mammals. For example, the β-casein gene can be deleted in mice. The resulting mice are healthy and fertile, but the growth of their pups is reduced. Similarly, mice lacking the κ-casein gene are healthy, but they did not suckle their pups and failed to lactate, hence the gene is required for reproductive success.

The American black bear (Ursus americanus), or simply black bear, is a species of medium-sized bear which is endemic to North America. It is the continent's smallest and most widely distributed bear species. It is an omnivore, with a diet varying greatly depending on season and location. It primarily inhabits forested regions, but may venture beyond forest boundaries in search of food. Individuals are occasionally drawn to human settlements due to the availability of easily accessible food sources. The International Union for Conservation of Nature (IUCN) lists the American black bear as a least-concern species because of its widespread distribution and a large population, estimated to be twice that of all other bear species combined. Along with the brown bear (Ursus arctos), it is one of the two modern bear species not considered by the IUCN to be globally threatened with extinction.

== Pathways == The protein C pathways are the specific chemical reactions that control the level of expression of APC and its activity in the body. Protein C is pleiotropic, with two main classes of functions: anticoagulation and cytoprotection (its direct effect on cells). Which function protein C performs depends on whether or not APC remains bound to EPCR after it is activated; the anticoagulative effects of APC occur when it does not. In this case, protein C functions as an anticoagulant by irreversibly proteolytically inactivating Factor Va and Factor VIIIa, turning them into Factor Vi and Factor VIIIi respectively. When still bound to EPCR, activated protein C performs its cytoprotective effects, acting on the effector substrate PAR-1, protease-activated receptor-1. To a degree, APC's anticoagulant properties are independent of its cytoprotective ones, in that expression of one pathway is not affected by the existence of the other. The activity of protein C may be down-regulated by reducing the amount either of available thrombomodulin or of EPCR. This may be done by inflammatory cytokines, such as interleukin-1β (IL-1β ) and tumor necrosis factor-α (TNF-α). Activated leukocytes release these inflammatory mediators during inflammation, inhibiting the creation of both thrombomodulin and EPCR, and inducing their shedding from the endothelial surface. Both of these actions down-regulate protein C activation. Thrombin itself may also have an effect on the levels of EPCR.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Is AOD-9604 the same as human growth hormone?

No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.

Does AOD-9604 occur naturally?

The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.

How is AOD-9604 thought to work?

It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.

Network